Trial | NCT01468441  Report issue

Title

Ovarian Stimulation Using Recombinant Follicle-stimulating Hormone (FSH) and Gonadotrophin Releasing Hormone (GnRH) Agonist in Alternate Days
Effect of Ovarian Stimulation Using Recombinant FSH and GHRH Antagonist in Alternate Days on ICSI Outcomes

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    96
The present prospective study was designed to compare the effects of administering a daily dose of gonadotrophin releasing hormone (GnRH) antagonist vs. an alternate-day dosage of GnRH agonist on ovarian response and in vitro fertilization (IVF) outcome in patients stimulated with recombinant follicle-stimulating hormone (FSH) and human chorionic gonadotrophin (hCG) microdose.
Inclusion criteria were as follows: women of good physical and mental health, under 37 years old, with regular menstrual cycles of 25-35 days, normal basal FSH and luteinizing hormone (LH) levels, body mass index (BMI) less than 30 kg/m2, presence of both ovaries and intact uterus, absence of polycystic ovaries, endometriosis, or gynaecological / medical disorders and a negative result in a screening for sexually transmitted diseases.

No patient had received any hormone therapy for at least 60 days preceding the study. Eligible patients who agreed to participate were randomized in two treatment groups. Patients were allocated to a GnRH analogue treatment group according to a computer-generated randomization table.
Study Started
Sep 30
2011
Primary Completion
Mar 31
2012
Study Completion
Mar 31
2012
Last Update
Jul 13
2012
Estimate

Drug Triptorelin

Triptorelin (0.1 mg, Gonapeptyl® Daily; Ferring, Kiel, Germany) in alternate-days from Day 1 of the menstrual cycle until the day of hCG administration.

  • Other names: Gonapeptyl

Drug Cetrorelix

When patients presented at least two follicles ≥ 14mm upon scan on days 7- 9, GnRH antagonist (cetrorelix, 0.25 mg/day, Cetrotide®; EMD Serono, Inc, Rockland, MA, USA) administration is started and continued until hCG administration.

  • Other names: Cetrotide

GnRH agonist Experimental

Administration of GnRH agonist in alternate days, recombinant FSH and hCG microdose for ovarian stimulation.

GnRH antagonist Active Comparator

Daily administration of GnRH antagonist, recombinant FSH and hCG microdose for ovarian stimulation.

Criteria 

Inclusion Criteria:

women of good physical and mental health
under 37 years old, with regular menstrual cycles of 25-35 days
normal basal FSH and LH levels
BMI less than 30 kg/m2
presence of both ovaries and intact uterus
absence of polycystic ovaries
endometriosis, or gynaecological / medical disorders and a negative result in a screening for sexually transmitted diseases
all patients signed a written informed consent form
no patient had received any hormone therapy for at least 60 days preceding the study.
No Results Posted